Skip to main content

Table 2 Susceptibility of the Moraxella catarrhalis isolates in Youyang, Zhongjiang and total profiles according to EUCAST, CLSI and BSAC

From: β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China

  Antibiotics* Youyang Zhongjiang Total
I% R% MIC50 MIC90 MIC Range I% R% MIC50 MIC90 MIC Range I% R% MIC50 MIC90 MIC Range
EUCASTa AMP 2 4 0.016~ 16 2 6 0.032~ 12 2 6 0.032–12
AMC 0 0.19 0.38 0.016~ 0.38 0 0.25 0.25 0.016~ 0.38 0 0.25 0.25 0.016–0.38
CXM 8.9 0 2 4 0.023~ 8 18.2 1.3 3 6 0.047~ 16 12.9 0.6 3 6 0.047–16
CAZ 0.125 0.38 0.023~ 2 0.094 0.38 0.032~ 1 0.094 0.38 0.032–1
FEP 4.0 1.5 4 0.064~ 6 1.3 1.5 4 0.19~ 6 2.8 1.5 4 0.19–6
CIP 2.0 0.047 0.19 0.016~ 1 5.2 0.047 0.094 0.016~ 1 3.4 0.047 0.094 0.016–1
ERY 28.7 64.4 0.75 > 256 0.047~ > 256 11.7 79.2 2 > 256 0.19~ > 256 21.3 70.8 2 256 0.19- > 256
MEM 0 0.006 0.008 0.003~ 0.38 0 0.006 0.008 0.003~ 0.023 0 0.006 0.008 0.003–0.38
TCY 3.0 5.9     0 3.9     1.7 5.1    
CHL 4.0     3.9     3.9    
SXT 9.9 30.7     7.8 3.9     9.0 19.1    
CLSIb AMC 0 0.19 0.38 0.016~ 0.38 0 0.25 0.25 0.016~ 0.38 0 0.25 0.25 0.016–0.38
CXM 8.9 0 2 4 0.023~ 8 18.2 1.3 3 6 0.047~ 16 12.9 0.6 3 6 0.047–16
CAZ -# -# 0.125 0.38 0.023~ 2 -# -# 0.094 0.38 0.032~ 1 -# -# 0.094 0.38 0.032–1
CIP -# -# 0.047 0.19 0.016~ 1 -# -# 0.047 0.094 0.016~ 1 -# -# 0.047 0.094 0.016–1
ERY 48.5 15.8 0.75 > 256 0.047~ > 256 44.1 35.1 2 > 256 0.19~ > 256 47.8 23.0 2 > 256 0.19- > 256
TCY 20.8 5.9     3.9 3.9     13.5 5.1    
SXT 6.9 16.8     0 1.3     3.9 10.1    
BSACc AMP 68.3 2 4 0.016~ 16 81.8 2 6 0.032~ 12 74.2 2 6 0.032–12
CXM 45.5 49.5 2 4 0.023~ 8 44.2 53.2 3 6 0.047~ 16 44.9 51.1 3 6 0.047–16
TCY 5.9     3.9     5.1    
SXT 19.8     1.3     11.8    
  1. aEUCAST European Committee on Antimicrobial Susceptibility Testing, bCLSI Clinical and Laboratory Standards Institute, cBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints were listed in the according criterion, but the other “-“s mean no data